Procter and Gamble earnings for the September quarter were steady where it counted and soft where it did not. Sales grew 4%, driven by more units sold, and the company raised its full-year sales outlook. Profit per share barely moved, though, and P&G told investors that rising costs will take a visible bite out of the year. Shares rose 5.6% on Thursday, according to a Reuters report, as the market focused on the first part.
The numbers come from P&G’s results release, which it filed with the SEC on October 22 for the first quarter of fiscal 2027.
What the Procter and Gamble earnings numbers show
Net sales were $23.3 billion, up 4% from a year earlier. Organic sales, which strip out currency and deals, also rose 4%. P&G said volume grew 2.4%, product mix added 1.1%, and price added only 0.4%.
That mix matters. For a household-goods company, selling more boxes is a healthier sign than raising prices on the same boxes. P&G’s own mix suggests the growth came from volume and not from leaning on price increases.
Core earnings per share were $2.00, up 1% from $1.99. Adjusted for currency, they were flat. Reported earnings per share were $1.97, up 1%. In other words, nearly all of the sales gain was absorbed by costs.
The timing of the report helped. Thursday was a lopsided day on Wall Street, with the Nasdaq down 2.6% while P&G rose 5.6%. The Reuters report quoted one strategist who said technology was the only sector really suffering. A steady maker of detergent and razors looked like shelter.
Where the growth came from
Four of the five business segments grew organically by at least 3%. Fabric and Home Care, the biggest, rose 4.8% on $8.2 billion in sales. Beauty grew 5.4%. Grooming grew 4.5%, and Baby, Feminine and Family Care grew 3.0%. Health Care was the slowest at 2.7%, though it posted the biggest profit gain of the group, up 10% before tax.
Baby, Feminine and Family Care was the only segment whose pre-tax earnings fell, down 4% despite higher sales. The results table does not say why.
The margin squeeze
The gross margin tells the cost story. P&G’s core gross margin was 50.0%, down 1.5 percentage points. The release breaks the drop into pieces. Higher commodity costs took off 1.4 points. Reinvestment in products took off another 1.4 points. Productivity savings gave back 1.2 points, and tariff-related benefits added 0.5.
That last item is worth a second look. P&G reported a tariff benefit of 50 basis points to gross margin this quarter, from lower costs and recoveries. It did not give a separate full-year tariff outlook.
Cash was healthy. Free cash flow was $4.4 billion, which P&G calls 93% productivity. Looking ahead, P&G still plans dividends above $10 billion and share repurchases of about $5 billion for the year. It returned $3.9 billion to shareholders in the quarter alone, about $2.6 billion in dividends and $1.25 billion in share repurchases.
Guidance: higher sales, same earnings range
The full-year outlook is where the Procter and Gamble earnings report gets complicated. P&G raised its all-in sales growth forecast to between 2% and 4%. The reason is an acquisition. The company bought the supplements maker Thorne, effective October 1, and its sales now count in the total.
Organic sales growth, which excludes the deal, stays at 1% to 3%. The core earnings forecast also stays put, at between flat and up 3% from last year’s $6.89 a share. That works out to a range of about $6.89 to $7.11.
The organic forecast also carries a built-in headwind. P&G said brand, product form, and go-to-market discontinuations will take 30 to 50 basis points off organic growth this year. In plain terms, the company is dropping some products and ways of selling them, and the lost sales count against it.
P&G was specific about the pressure. It expects about $1.4 billion after tax in higher costs for raw materials, energy and transportation. It also cited higher interest expense, lower non-operating income and currency. Together, the company said, they add up to a 79-cent drag, or about 11% of core earnings growth.
The Thorne deal
P&G agreed in early August to pay $3.8 billion in cash for Thorne, according to ESM Magazine, which reported that the seller was the private equity firm L Catterton. The same report said CNBC had put Thorne’s expected sales this year near $650 million. It fits a push into health and wellness. P&G already sells New Chapter, Metamucil and Align Probiotic.
An acquisition lifts the top line. It does not make the core business grow faster, and P&G kept its organic forecast where it was. That is why the stock reaction and the Procter and Gamble earnings guidance tell slightly different stories.
What the Procter and Gamble earnings mean for investors and shoppers
Two readings fit the quarter. The optimistic one is that P&G is growing volume in a tough year and absorbing cost pressure without cutting its earnings range. The cautious one is that the company’s growth depends on productivity gains and a deal to keep pace.
For shoppers, a company that grew mostly through volume is not signaling a new round of broad price increases. It is also not promising to hold prices. We have seen the same cost pressures play out at the airlines, where our look at United Airlines earnings showed fuel costs cutting into profit despite record sales. And GM’s quarter, which ended in a narrowed outlook, showed another version of the same squeeze.
This is general information, not investment advice.
Editor’s take
The headline on the Procter and Gamble earnings is that sales rose and guidance went up. The footnote says earnings did not move. We would trust the footnote. P&G is a good test of whether big consumer brands can protect profit when costs rise and shoppers push back on price. This quarter says they can, barely. Watch the gross margin line in the next report. If it falls again while volume slows, the earnings range is at risk.
